Fairmount Funds Management, Director: Cogent Biosciences COGT Planned sale · Filed 01/22

Trade details

Type: Planned sale notice
Stock: Cogent Biosciences COGT
Person: Fairmount Funds ManagementDirector
Planned sale date: 26/01/22
Filed: 26/01/22

2.3% of shares outstanding to be sold

Cogent Biosciences trades, last 26 weeks

What else happened in Cogent Biosciences around then

Filed or reported within 30 days of the trade day · 25/12/23~02/21

Fairmount Funds Management's recent trades

Fairmount Funds ManagementDirector, 10% Stockholder
Planned saleOruka Therapeutics
Planned sale
Oruka Therapeutics
ORKA
$300M
3,553,410 sh
$300M
Filed 07/01
Traded 07/01
Fairmount Funds ManagementDirector
Planned saleSpyre Therapeutics
Planned sale
Spyre Therapeutics
SYRE
$399.7M
4,684,781 sh
$399.7M
Filed 06/23
Traded 06/23
Fairmount Funds ManagementDirector
SellSpyre Therapeutics
Sell
Spyre Therapeutics
SYRE
$399.7M
4,684,781 sh
$399.7M
Filed 06/23
Traded 06/23
Fairmount Funds ManagementDirector
BuyViridian Therapeutics, Inc.\DE
Buy
Viridian Therapeutics, Inc.\DE
VRDN
$20M
1,176,470 sh
$20M
Filed 05/13
Traded 05/11
Fairmount Funds ManagementDirector
BuyZenas BioPharma
Buy
Zenas BioPharma
ZBIO
$3M
150,000 sh
$3M
Filed 04/01
Traded 03/31

Fairmount Funds Management, Director — plans to sell 3,500,000 sh of Cogent Biosciences COGT · $127.4M · around 01/22 | Whalegun